BC
IDYA icon

Bridgefront Capital’s IDEAYA Biosciences IDYA Stock Holding History

Bridgefront Capital’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,363
Closed -$212K – 635
2026
Q1 		$212K Sell
6,363
-29,842
-82% -$1M 0.05% 469
2025
Q4 		$1.25M Buy
+36,205
New +$1.15M 0.31% 90

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bridgefront Capital's IDYA Position: Q2 2026 in Review

Bridgefront Capital sold out of IDEAYA Biosciences (IDYA) in Q2 2026, closing a stake of 6,363 shares — an estimated $212K sold.

Bridgefront Capital first reported a position in IDYA in Q4 2025 and held it in 2 quarters. The position peaked at $1.25M in Q4 2025. 285 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Bridgefront Capital reported no remaining IDEAYA Biosciences position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 6,363 IDEAYA Biosciences shares in Q2 2026, an estimated $212K.
  • Bridgefront Capital first reported a position in IDEAYA Biosciences in Q4 2025 and held it in 2 quarters.
  • Bridgefront Capital's IDEAYA Biosciences position peaked at $1.25M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.